scholarly journals In vivo Dynamics and Distinct Functions of Hypoxia in Primary Tumor Growth and Organotropic Metastasis of Breast Cancer

2010 ◽  
Vol 70 (10) ◽  
pp. 3905-3914 ◽  
Author(s):  
Xin Lu ◽  
Carol H. Yan ◽  
Min Yuan ◽  
Yong Wei ◽  
Guohong Hu ◽  
...  
2020 ◽  
Vol 117 (45) ◽  
pp. 28056-28067
Author(s):  
Nuthasuda Srijakotre ◽  
Heng-Jia Liu ◽  
Max Nobis ◽  
Joey Man ◽  
Hon Yan Kelvin Yip ◽  
...  

The Rac-GEF, P-Rex1, activates Rac1 signaling downstream of G protein-coupled receptors and PI3K. Increased P-Rex1 expression promotes melanoma progression; however, its role in breast cancer is complex, with differing reports of the effect of its expression on disease outcome. To address this we analyzed human databases, undertook gene array expression analysis, and generated unique murine models of P-Rex1 gain or loss of function. Analysis ofPREX1mRNA expression in breast cancer cDNA arrays and a METABRIC cohort revealed that higherPREX1mRNA in ER+ve/luminal tumors was associated with poor outcome in luminal B cancers.Prex1deletion in MMTV-neuor MMTV-PyMTmice reduced Rac1 activation in vivo and improved survival. High level MMTV-driven transgenicPREX1expression resulted in apicobasal polarity defects and increased mammary epithelial cell proliferation associated with hyperplasia and development of de novo mammary tumors. MMTV-PREX1expression in MMTV-neumice increased tumor initiation and enhanced metastasis in vivo, but had no effect on primary tumor growth. Pharmacological inhibition of Rac1 or MEK1/2 reduced P-Rex1-driven tumoroid formation and cell invasion. Therefore, P-Rex1 can act as an oncogene and cooperate with HER2/neu to enhance breast cancer initiation and metastasis, despite having no effect on primary tumor growth.


Oncotarget ◽  
2017 ◽  
Vol 8 (38) ◽  
pp. 63881-63889 ◽  
Author(s):  
Yuji Wang ◽  
Xinyi Xu ◽  
Ce Song ◽  
Jianhui Wu ◽  
Xi Hu ◽  
...  

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 217 ◽  
Author(s):  
Eileen Shiuan ◽  
Ashwin Inala ◽  
Shan Wang ◽  
Wenqiang Song ◽  
Victoria Youngblood ◽  
...  

Background: The conventional dogma of treating cancer by focusing on the elimination of tumor cells has been recently refined to include consideration of the tumor microenvironment, which includes host stromal cells. Ephrin-A1, a cell surface protein involved in adhesion and migration, has been shown to be tumor suppressive in the context of the cancer cell. However, its role in the host has not been fully investigated. Here, we examine how ephrin-A1 host deficiency affects cancer growth and metastasis in a murine model of breast cancer. Methods: 4T1 cells were orthotopically implanted into the mammary fat pads or injected into the tail veins of ephrin-A1 wild-type (Efna1+/+), heterozygous (Efna1+/-), or knockout (Efna1-/-) mice. Tumor growth, lung metastasis, and tumor recurrence after surgical resection were measured. Flow cytometry and immunohistochemistry (IHC) were used to analyze various cell populations in primary tumors and tumor-bearing lungs. Results: While primary tumor growth did not differ between Efna1+/+, Efna1+/-, and Efna1-/- mice, lung metastasis and primary tumor recurrence were significantly decreased in knockout mice. Efna1-/- mice had reduced lung colonization of 4T1 cells compared to Efna1+/+ littermate controls as early as 24 hours after tail vein injection. Furthermore, established lung lesions in Efna1-/- mice had reduced proliferation compared to those in Efna1+/+ controls. Conclusions: Our studies demonstrate that host deficiency of ephrin-A1 does not impact primary tumor growth but does affect metastasis by providing a less favorable metastatic niche for cancer cell colonization and growth. Elucidating the mechanisms by which host ephrin-A1 impacts cancer relapse and metastasis may shed new light on novel therapeutic strategies.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22103-e22103
Author(s):  
Yang Xu ◽  
Bo Hu ◽  
Robert Anders ◽  
Anirban Maitra ◽  
Jia Fan

e22103 Background: Curcumin regulates the expression and secretion of MMPs, and has potent anti-cancer properties in several human cancer cell lines and animal carcinogenesis models. In this study we try to investigate the effects of polymeric nanoparticle encapsulated formulation of curcumin– nanocurcumin (NC) on Hepatocellular carcinoma (HCC) in vitro and in vivo. Methods: The effects of NC alone and in combination with sorafenib (SO) were investigated on HCC cell lines, Huh7 and MHCCLM3 in vitro by using proliferation and invasion assay, western blot, qRT-PCR, enzyme-linked immunosorbent assay and immunohistochemistry staining, and the subcutaneous and orthotopic HCC xenograft nude mice models (MHCCLM3) were used to evaluate primary tumor growth and metastasis after treatments. Results: NC alone (or combined with SO)inhibited HCC cell proliferation (p<0.05) and invasion in vitro (p<0.01), and remarkably decreased both the subcutaneous and orthotopic primary tumor growth and lung metastases in vivo. NC and/or SO could down-regulating the expressions of Matrix Metalloproteinase-9 (MMP9), p-ERK1 and NF-kB/p65 (p<0.05). Conclusions: NC showed potent anti-invasion and metastasis properties in HCC via NF-κB mediated MMP9 down-regulation, which may provide a new strategy to the treatment of HCC patients and prevention of tumor recurrence after operation.


2012 ◽  
Vol 14 (1) ◽  
Author(s):  
Luciana P Schwab ◽  
Danielle L Peacock ◽  
Debeshi Majumdar ◽  
Jesse F Ingels ◽  
Laura C Jensen ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e29615 ◽  
Author(s):  
Manisha Shah ◽  
Dexing Huang ◽  
Tony Blick ◽  
Andrea Connor ◽  
Lawrence A. Reiter ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document